Aripiprazole transdermal - Aequus Pharmaceuticals

Drug Profile

Aripiprazole transdermal - Aequus Pharmaceuticals

Alternative Names: AQS-1301; Transdermal aripiprazole - Aequus

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aequus Pharmaceuticals
  • Developer Aequus Pharmaceuticals; Corium International
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor partial agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Autistic disorder; Bipolar disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 16 Nov 2017 Aequus Pharmaceuticals has patent protection for Aripiprazole transdermal in Europe, USA, Russia, Mexico, Canada and Australia
  • 10 Oct 2017 Aequus Pharmaceuticals has patent protection for aripiprazole transdermal for psychiatric disorders in China
  • 10 Oct 2017 Aequus Pharmaceuticals has patent protection for aripiprazole transdermal in USA and Canada before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top